{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:40:19Z","timestamp":1784875219959,"version":"3.55.0"},"reference-count":60,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004417","name":"Global Fund to Fight AIDS, Tuberculosis and Malaria","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prior to 2020, treatment options for multidrug-resistant tuberculosis (MDR-TB) were limited and typically involved long treatment durations and high financial burdens. In the eastern European and central Asian (EECA) region, traditional inpatient tuberculosis (TB) care models, alongside high MDR-TB rates, escalate nosocomial transmission risks and treatment costs. Modified, fully oral, shorter treatment regimens (mSTR) implemented in the WHO European Region under operational research conditions offered a potential reduction in the burden of MDR-TB treatment for both patients and health systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted the first regional evaluation of the cost-effectiveness of the novel mSTR treatment regimen compared with the standard of care (SOC) in Belarus, Georgia, Kazakhstan and Republic of Moldova. We used cohort data on mSTR efficacy and WHO data on SOC in patients with MDR-TB. We used a Markov model, with treatment costs calculated from the provider perspective. Outcomes were measured in quality-adjusted life years (QALYs), with incremental cost-effectiveness ratios (ICER) calculated per QALY gained in each country. An annual 3% discount rate was used for both costs and outcomes. We performed univariate and probabilistic sensitivity analysis (PSA) to assess the robustness of our cost-effectiveness calculations under varying assumptions. Finally, we estimated potential cost savings if mSTR was implemented nationally and we evaluated the incremental net monetary benefit (iNMB) and willingness-to-pay (WTP) thresholds based on Wood\n                      <jats:italic>et al<\/jats:italic>\n                      \u2019s country-level cost-effectiveness thresholds. All costs were reported in 2022 USD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We estimated that mSTR can reduce TB treatment costs by between 23%\u2009and 47% and drug costs by 39% to 74%, compared with SOC in the countries studied. mSTR resulted in cost savings of between $3596 and $8174 per patient and offered additional health gains of between 0.56 to 2.69 QALYs per patient. mSTR remained cost-effective (iNMB&gt;0) compared with SOC in 78%, 85%, 91% and 92% of PSA simulations in Belarus, Georgia, Kazakhstan and Republic of Moldova, respectively, when compared with their country-level WTP threshold. Implementing mSTR in up to 80% of MDR\/rifampicin-resistant TB patients may result in cost savings of $20.5, 2.5, 0.7 and 0.2\u2009million in Kazakhstan, Belarus, Republic of Moldova and Georgia; equivalent to 17%, 3%, 4% and 1% of their national TB budgets, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with SOC, mSTR is a more cost-effective treatment option for MDR\/RR-TB, which should be considered by policymakers in the EECA region. Using insights from current implementations to scale up, plan operational changes and reallocate savings from mSTR could greatly enhance TB services and patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2024-018099","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:10:11Z","timestamp":1762629011000},"page":"e018099","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova"],"prefix":"10.1136","volume":"10","author":[{"given":"Kasim","family":"Allel","sequence":"first","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, Oxfordshire, UK"},{"name":"Institute for Global Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-0045","authenticated-orcid":false,"given":"Tom","family":"Palmer","sequence":"additional","affiliation":[{"name":"Institute for Global Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6022-3036","authenticated-orcid":false,"given":"Gerard Joseph","family":"Abou Jaoude","sequence":"additional","affiliation":[{"name":"Institute for Global Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Korotych","sequence":"additional","affiliation":[{"name":"World Health Organization Regional Office for Europe, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Askar","family":"Yedilbayev","sequence":"additional","affiliation":[{"name":"World Health Organization Regional Office for Europe, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vilc","sequence":"additional","affiliation":[{"name":"Institute of Phthisiopneumology, Chisinau, Moldova (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Corloteanu","sequence":"additional","affiliation":[{"name":"Institute of Phthisiopneumology, Chisinau, Moldova (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Macari","sequence":"additional","affiliation":[{"name":"Institute of Phthisiopneumology, Chisinau, Moldova (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cula","family":"Evghenia","sequence":"additional","affiliation":[{"name":"Institute of Phthisiopneumology, Chisinau, Moldova (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Laticevschi","sequence":"additional","affiliation":[{"name":"The Global Fund to Fight AIDS Tuberculosis and Malaria, Grand-Saconnex, Gen\u00e8ve, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismailov","family":"Shakhimurat-Shaimovich","sequence":"additional","affiliation":[{"name":"National Scientific Center of Phthisiopulmonology of the Republic of Kazakhstan, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakisheva","family":"Anar-Saduakasovna","sequence":"additional","affiliation":[{"name":"National Scientific Center of Phthisiopulmonology of the Republic of Kazakhstan, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulepova","family":"Gulzhan-Elbrusovna","sequence":"additional","affiliation":[{"name":"National Scientific Center of Phthisiopulmonology of the Republic of Kazakhstan, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Anatolievna-Ryazanet","sequence":"additional","affiliation":[{"name":"National Scientific Center of Phthisiopulmonology of the Republic of Kazakhstan, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimbekova","family":"Shahrizada-Yergalymovna","sequence":"additional","affiliation":[{"name":"National Scientific Center of Phthisiopulmonology of the Republic of Kazakhstan, Almaty, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Yatskevich","sequence":"additional","affiliation":[{"name":"Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Skrahina","sequence":"additional","affiliation":[{"name":"Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Zhurkin","sequence":"additional","affiliation":[{"name":"Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Avaliani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kiria","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Lomtadze","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Kiria","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teona","family":"Avaliani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Khonelidze","sequence":"additional","affiliation":[{"name":"National Center for Disease Control and Public Health, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maka","family":"Danelia","sequence":"additional","affiliation":[{"name":"National Center for Disease Control and Public Health, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Maxim","sequence":"additional","affiliation":[{"name":"The Global Fund to Fight AIDS Tuberculosis and Malaria, Grand-Saconnex, Gen\u00e8ve, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Haghparast-Bidgoli","sequence":"additional","affiliation":[{"name":"Institute for Global Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene","family":"Skordis","sequence":"additional","affiliation":[{"name":"Institute for Global Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"2025120102301206000_10.11.e018099.1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2025120102301206000_10.11.e018099.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30703-X"},{"key":"2025120102301206000_10.11.e018099.3","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO\u2019s Global Tuberculosis Report 2022","volume":"4","author":"Bagcchi","year":"2023","journal-title":"Lancet Microbe"},{"key":"2025120102301206000_10.11.e018099.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41937-9","article-title":"Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis","volume":"14","author":"Menzies","year":"2023","journal-title":"Nat Commun"},{"key":"2025120102301206000_10.11.e018099.5","unstructured":"World Health Organization . Global tuberculosis report 2023. 2023."},{"key":"2025120102301206000_10.11.e018099.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2025120102301206000_10.11.e018099.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03300-2020"},{"key":"2025120102301206000_10.11.e018099.8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3855\/jidc.3396","article-title":"TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia","volume":"7","author":"Gillini","year":"2013","journal-title":"J Infect Dev Ctries"},{"key":"2025120102301206000_10.11.e018099.9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4081\/monaldi.2020.1235","article-title":"Factors contributing to drug-resistant tuberculosis treatment outcome in five countries in the Eastern Europe and Central Asia region","volume":"90","author":"Auer","year":"2020","journal-title":"Monaldi Arch Chest Dis"},{"key":"2025120102301206000_10.11.e018099.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001025","article-title":"Public health benefits of shifting from hospital-focused to ambulatory TB care in Eastern Europe: Optimising TB investments in Belarus, the Republic of Moldova, and Romania","volume":"3","author":"Kelly","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2025120102301206000_10.11.e018099.11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1473-3099(19)30568-7","article-title":"Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data","volume":"20","author":"Dadu","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2025120102301206000_10.11.e018099.12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(16)30856-X","article-title":"The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia","volume":"388","author":"Altice","year":"2016","journal-title":"The Lancet"},{"key":"2025120102301206000_10.11.e018099.13","unstructured":"Organization WH . WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment: World Health Organization. 2020."},{"key":"2025120102301206000_10.11.e018099.14","unstructured":"World Health Organization . Regional operational research on the introduction of fully oral modified shorter treatment regimens for multidrug\/rifampicin-resistant tuberculosis: mid-project evaluation. Regional operational research on the introduction of fully oral modified shorter treatment regimens for multidrug\/rifampicin-resistant tuberculosis: mid-project evaluation. 2023."},{"key":"2025120102301206000_10.11.e018099.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001337","article-title":"Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis","volume":"2","author":"Sweeney","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2025120102301206000_10.11.e018099.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"2025120102301206000_10.11.e018099.17","unstructured":"Organization WH . WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. World Health Organization; 2022."},{"key":"2025120102301206000_10.11.e018099.18","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.cmi.2024.03.009","article-title":"Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe","volume":"30","author":"G\u00fcnther","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2025120102301206000_10.11.e018099.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01249-2016"},{"key":"2025120102301206000_10.11.e018099.20","unstructured":"World Health Organization . Tuberculosis regional Estern-European and Central-Asian project. 2018. Available: https:\/\/www.euro.who.int\/en\/health-topics\/communicable-diseases\/tuberculosis\/publications\/2017\/tuberculosis-regional-eastern-european-and-central-asian-project-tb-rep-mid-term-update-2017 [Accessed 16 Jun 2023]."},{"key":"2025120102301206000_10.11.e018099.21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1473-3099(24)00228-7","article-title":"Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study","volume":"24","author":"Korotych","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120102301206000_10.11.e018099.22","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"2025120102301206000_10.11.e018099.23","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454577"},{"key":"2025120102301206000_10.11.e018099.24","doi-asserted-by":"crossref","unstructured":"Korotych O , Achar J , Gurbanova E , et al . Effectiveness and safety of modified fully oral nine-month treatment regimens for rifampicin-resistant tuberculosis: prospective cohort study. SSRN [Preprint]. doi:10.2139\/ssrn.4729025","DOI":"10.2139\/ssrn.4729025"},{"key":"2025120102301206000_10.11.e018099.25","unstructured":"Organization WH . WHO consolidated guidelines on drug-resistant tuberculosis treatment: World Health Organization. 2019."},{"key":"2025120102301206000_10.11.e018099.26","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01714-18"},{"key":"2025120102301206000_10.11.e018099.27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01467-2019","article-title":"Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis","volume":"55","author":"Abidi","year":"2020","journal-title":"Eur Respir J"},{"key":"2025120102301206000_10.11.e018099.28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2213-2600(20)30039-4","article-title":"Post-tuberculosis mortality and morbidity: valuing the hidden epidemic","volume":"8","author":"Quaife","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025120102301206000_10.11.e018099.29","unstructured":"Institute for Health Metrics and Evaluation . Global burden of disease study 2019 (GBD 2019) data resources. Seattle, Washington, 2019."},{"key":"2025120102301206000_10.11.e018099.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7133.736"},{"key":"2025120102301206000_10.11.e018099.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5376","article-title":"Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"},{"key":"2025120102301206000_10.11.e018099.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.015"},{"key":"2025120102301206000_10.11.e018099.33","unstructured":"Global Drug Facility . Medicines catalog. 2021. Available: https:\/\/stoptb.org\/assets\/documents\/gdf\/drugsupply\/GDFMedicinesCatalog.pdf [Accessed 22 Jun 2023]."},{"key":"2025120102301206000_10.11.e018099.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.02.017"},{"key":"2025120102301206000_10.11.e018099.35","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/0272989X241262343","article-title":"Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty","volume":"44","author":"Yaesoubi","year":"2024","journal-title":"Med Decis Making"},{"key":"2025120102301206000_10.11.e018099.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00358.x"},{"key":"2025120102301206000_10.11.e018099.37","unstructured":"World Health Organization . Tuberculosis finance profile. 2023. Available: https:\/\/app.powerbi.com\/view?r=eyJrIjoiMGIwZDUzMmItODE5Yi00YjAzLTliMGEtNGVhMGVlYzA4YWVkIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9 [Accessed 21 Oct 2023]."},{"key":"2025120102301206000_10.11.e018099.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051521","article-title":"Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines","volume":"11","author":"Gomez","year":"2021","journal-title":"BMJ Open"},{"key":"2025120102301206000_10.11.e018099.39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-007182","article-title":"Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis","volume":"7","author":"Mulder","year":"2022","journal-title":"BMJ Glob Health"},{"key":"2025120102301206000_10.11.e018099.40","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2214-109X(24)00467-4","article-title":"24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation","volume":"13","author":"Sweeney","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2025120102301206000_10.11.e018099.41","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00498-3"},{"key":"2025120102301206000_10.11.e018099.42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12913-016-1344-3","article-title":"The evolution of the health system outcomes in Central and Eastern Europe and their association with social, economic and political factors: an analysis of 25 years of transition","volume":"16","author":"Romaniuk","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2025120102301206000_10.11.e018099.43","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0279-6"},{"key":"2025120102301206000_10.11.e018099.44","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1473-3099(24)00007-0","article-title":"Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021","volume":"24","author":"Ledesma","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120102301206000_10.11.e018099.45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.5588\/ijtld.20.0174","article-title":"Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?","volume":"24","author":"Ndjeka","year":"2020","journal-title":"int j tuberc lung dis"},{"key":"2025120102301206000_10.11.e018099.46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5588\/ijtld.22.0536","article-title":"Primary bedaquiline resistance in Karakalpakstan, Uzbekistan","volume":"27","author":"Moe","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025120102301206000_10.11.e018099.47","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025120102301206000_10.11.e018099.48","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur Respir J"},{"key":"2025120102301206000_10.11.e018099.49","doi-asserted-by":"crossref","DOI":"10.4103\/2212-5531.307132","article-title":"High frequency of bedaquiline resistance in programmatically treated drug-resistant TB patients with sustained culture-positivity in Cape Town, South Africa","volume":"10","author":"Derendinger","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"2025120102301206000_10.11.e018099.50","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2217\/fmb-2020-0089","article-title":"Overcoming Drug resistance in TB: An Update","volume":"15","author":"Consalvi","year":"2020","journal-title":"Future Microbiol"},{"key":"2025120102301206000_10.11.e018099.51","doi-asserted-by":"publisher","DOI":"10.1378\/chest.76.6.771"},{"key":"2025120102301206000_10.11.e018099.52","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00470-9"},{"key":"2025120102301206000_10.11.e018099.53","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"The Lancet Microbe"},{"key":"2025120102301206000_10.11.e018099.54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(23)00550-9","article-title":"Minimising the threat of bedaquiline-resistant tuberculosis: better diagnosis as prevention","volume":"24","author":"Zemanay","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120102301206000_10.11.e018099.55","unstructured":"ClinicalTrials.Gov id NCT05555303. Preventing acquired resistance: strengthen TB treatment by adding amikacin in the first treatment week of multidrug-resistant tuberculosis (stake). 2023."},{"key":"2025120102301206000_10.11.e018099.56","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025120102301206000_10.11.e018099.57","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00632-20"},{"key":"2025120102301206000_10.11.e018099.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.01.006"},{"key":"2025120102301206000_10.11.e018099.59","unstructured":"World Bank . GDP per capita (current US$). 2023. Available: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD [Accessed 20 Jun 2023]."},{"key":"2025120102301206000_10.11.e018099.60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-018099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:30:41Z","timestamp":1764585041000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-018099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":60,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,8]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjgh-2024-018099"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-018099","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}